Capital World Investors
UBX

Capital World Investors’s Unity Biotechnology UBX Stock Holding History

Capital World Investors’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-183,500
Closed -$15.9M – 568
2020
Q2 		$15.9M Hold
183,500
– – ﹤0.01% 454
2020
Q1 		$10.6M Hold
183,500
– – ﹤0.01% 442
2019
Q4 		$13.2M Hold
183,500
– – ﹤0.01% 453
2019
Q3 		$11.2M Hold
183,500
– – ﹤0.01% 458
2019
Q2 		$17.4M Hold
183,500
– – ﹤0.01% 454
2019
Q1 		$14.9M Buy
183,500
+37,411
+26% +$4.24M ﹤0.01% 462
2018
Q4 		$23.8M Buy
146,089
+42,589
+41% +$5.65M 0.01% 419
2018
Q3 		$16.9M Buy
103,500
+81,551
+372% +$13.4M ﹤0.01% 479
2018
Q2 		$3.31M Buy
+21,949
New +$3.21M ﹤0.01% 521

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capital World Investors's UBX Position: Q3 2020 in Review

Capital World Investors sold out of Unity Biotechnology (UBX) in Q3 2020, closing a stake of 183,500 shares — an estimated $15.9M sold.

Capital World Investors first reported a position in UBX in Q2 2018 and held it in 9 quarters. The position peaked at $23.8M in Q4 2018. 79 funds tracked by Wall St. Rank hold UBX as of Q3 2020.

  • Capital World Investors reported no remaining Unity Biotechnology position as of Q3 2020 after selling out during the quarter.
  • Capital World Investors sold 183,500 Unity Biotechnology shares in Q3 2020, an estimated $15.9M.
  • Capital World Investors first reported a position in Unity Biotechnology in Q2 2018 and held it in 9 quarters.
  • Capital World Investors's Unity Biotechnology position peaked at $23.8M in Q4 2018.
  • 79 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2020.

Based on Capital World Investors's 13F filing for Q3 2020, filed 13 Nov 2020.